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OBJECTIVEdYoung children have an unacceptably high prevalence of diabetic ketoacidosis
(DKA) at the clinical diagnosis of type 1 diabetes. The aim of this study was to determine whether
knowledge of genetic risk and close follow-up for development of islet autoantibodies through
participation in The Environmental Determinants of Diabetes in the Young (TEDDY) study
results in lower prevalence of DKA at diabetes onset in children aged,2 and,5 years compared
with population-based incidence studies and registries.
RESEARCH DESIGN AND METHODSdSymptoms and laboratory data collected on
TEDDY participants diagnosed with type 1 diabetes between 2004 and 2010 were compared with
data collected during the similar periods from studies and registries in all TEDDY-participating
countries (U.S., SEARCH for Diabetes in Youth Study; Sweden, Swediabkids; Finland, Finnish
Pediatric Diabetes Register; and Germany, Diabetes Patienten Verlaufsdokumenation [DPV]
Register).
RESULTSdA total of 40 children younger than age 2 years and 79 children younger than age
5 years were diagnosed with type 1 diabetes in TEDDY as of December 2010. In children
,2 years of age at onset, DKA prevalence in TEDDY participants was significantly lower than
in all comparative registries (German DPV Register, P , 0.0001; Swediabkids, P = 0.02;
SEARCH, P, 0.0001; Finnish Register, P, 0.0001). The prevalence of DKA in TEDDY children
diagnosed at,5 years of age (13.1%) was significantly lower compared with SEARCH (36.4%)
(P , 0.0001) and the German DPV Register (32.2%) (P , 0.0001) but not compared with
Swediabkids or the Finnish Register.
CONCLUSIONSdParticipation in the TEDDY study is associated with reduced risk of DKA
at diagnosis of type 1 diabetes in young children.
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Recent epidemiological studies indi-cate that the incidence of type 1diabetes is increasing worldwide,
with the greatest increase in children aged
,5 years (1). Perhaps most alarming is
that the diagnosis of type 1 diabetes in
children aged ,5 years is frequently as-
sociated with concurrent diabetic ketoa-
cidosis (DKA) (2–4). Depending on the
specific population studied and the defi-
nition of DKA used, the reported preva-
lence of DKA in children under 5 years of
age at diagnosis varies between 17.3 and
54.5% (3,5–9) (Table 1). When even
younger subsets of newly diagnosed pa-
tients with type 1 diabetes were evaluated,
DKA prevalence has been reported to be
as high as 39.7% in children aged ,3
years (2) and as high as 60% in children
aged ,2 years at diagnosis (3).
Prevention of DKA would eliminate
the potential morbidity and mortality as-
sociated with cerebral edema at diagnosis
and may provide considerable cost savings
by reducing days of hospitalization and use
of intensive care units. Previous studies of
autoantibody-positive children have dem-
onstrated fewer episodes of DKA, reduced
morbidity, and improved clinical care in
children diagnosed through prospective
screening and follow-up (10,11). In addi-
tion, the diagnosis of children at an earlier
stage of the disease (i.e., without metabolic
decompensation associated with DKA)
may afford children the preservation of
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remaining b-cell function, the opportunity
to participate in intervention trials, and the
possibility of fewer long-term complica-
tions (12).
Several ongoing studies are following
children at high genetic risk of type 1
diabetes from birth (13,14). Some of these
studies provide risk information to subjects
whereas some do not initially inform pa-
rents about their child’s type 1 diabetes
risk. Intensive follow-up of children with
genetic risk of type 1 diabetes in prospec-
tive studies, which includes ongoing pro-
vision of updated risk information, may
increase awareness of symptoms and en-
able early diagnosis of diabetes and preven-
tion of DKA (10). Additionally, routine
assessments of HbA1c, fasting plasma glu-
cose, and oral glucose tolerance tests
(OGTTs) in children with confirmed auto-
antibodies may allow diagnosis of type 1
diabetes prior to recognition of symptoms.
As such, the specific aim of this study
was to determine if participation in a
longitudinal study of the natural history
of type 1 diabetes, The Environmental
Determinants of Diabetes in the Young
(TEDDY), in which the parents of young
children (aged ,5 years) are aware of
their child’s increased risk for developing
the disease, resulted in lower rates of DKA
at diagnosis of type 1 diabetes compared
with recent and ongoing population-
based incidence registry studies con-
ducted in countries also participating in
TEDDY. Specifically, we hypothesized
that DKA prevalence in young children
participating in TEDDY (,2 years and
,5 years of age at diagnosis) would be
lower than the DKA rates of children par-
ticipating in an observational study,
SEARCH for Diabetes in Youth in the U.S.
(7) and national registries, Swediabkids
(Sweden) (15), the Finnish Pediatric Dia-
betes Register (16), and the German
Diabetes Patienten Verlaufsdokumenation
(DPV) Register (8).
RESEARCH DESIGN AND
METHODS
Participants
We compared symptoms and laboratory
results collected for children participating
in the TEDDY study (17) diagnosed with
type 1 diabetes between 1 January 2004
and 31 December 2010 with data from the
population-based SEARCH study andpop-
ulation based registries (Swediabkids,
Finnish Pediatric Diabetes Register, and
German DPV Register) from all participat-
ing countries in TEDDY for the same inci-
dent years (when available). In the TEDDY
study, children with genetic risk of type 1
diabetes are followed intensively from
3 months of age. TEDDY is a multicenter
study, with sites in Sweden, Finland, Ger-
many, and theU.S. (Colorado,Washington,
and Florida/Georgia). All children are
screened at birth for type 1 diabetes HLA
risk genotypes, and children at risk are
followed. The aim of TEDDY is to deter-
mine environmental factors associated
with the development of islet autoanti-
bodies and type 1 diabetes in children
with increased genetic risk of the disease.
Participating children are followed every
third month from 3months of age to mea-
sure height and weight, collect blood and
stool samples, and obtain responses to a
series of questionnaires. Blood samples at
each visit are analyzed for autoantibodies
against GAD, insulinoma associated pro-
tein 2, and insulin. In antibody-positive
children, random plasma glucose and
HbA1c are measured at each visit. Addi-
tionally, autoantibody-positive children
.3 years of age undergo OGTTs every 6
months. Parents are carefully informed
about diabetes risk and provided with
updated antibody results. Follow-up is in-
tended to continue until subjects reach 15
years of age.
Collection of data at diagnosis
of type 1 diabetes
At diagnosis of type 1 diabetes, data are
collected from the treating physician
using a standardized case report form
requiring documentation that American
Diabetes Association criteria for the di-
agnosis have been met (18). Data collec-
tion includes information on symptoms
and parameters of metabolic decompen-
sation, such as pH, urine ketones, blood
ketones (betahydroxybutyrate), and elec-
trolytes. Because routine care for children
with type 1 diabetes varies considerably
from site to site, the diagnosis form
includes a free text area allowing study staff
to extract information about the child’s
clinical status. This is critical for determin-
ing likely DKA status in children where no
laboratory evaluation was performed. In
some countries (i.e., Finland and Sweden),
nearly all children diagnosed with type 1
diabetes have blood obtained for assess-
ment of acid-base balance and are admitted
to a hospital for inpatient care. In other
countries, children without clinical signs
of DKA and mild symptoms are preferen-
tially treated as outpatients, and blood for
evaluation of acid-base balance is only
taken if the pediatrician suspects DKA or
if the child is critically ill.
National registries for comparison
For comparative analyses of DKA at onset,
we obtained data from national incidence
studies being performed in the same
countries as the TEDDY study (for the
European registers during 2004–2009 and
for the U.S. study during 2004–2005).
Data were limited to children ,5 years of
age at diagnosis.
Table 1dLiterature review of DKA at diagnosis in children under age 5 years
Study country (reference) Definition of DKA Time of diabetes onset
DKA frequency % (n)
,2 years of age ,3 years of age ,5 years of age
SEARCH, U.S. (7) 4 2002–2004 NA NA 37.3 (458)
Austria (3) 1 1989–2008 60 (185) NA 43.7 (775)
Germany (5) 3 1987–1997 NA NA 36.0 (470)
Germany and Austria (8) 1 1995–2007 NA NA 26.5 (NA)
Canada (2) 5 1994–2000 NA 39.7% (390) NA
Finland (6) 2 1992–2001 44.71, 54.22 (48) NA 23.71, 29.32 (137)
U.S. (9) 1 1995–1998 NA NA 54.5 (44)
NA, data not available. DKA defined as follows: 1 = pH,7.3; 2 = pH,7.3 and/or bicarbonate,15mmol/L; 3 = pH,7.3 or bicarbonate,15mmol/L and ketonuria;
4 = arterial or capillary pH,7.3/venous pH,7.25 or ICD 9 code 250.1 at discharge or DKA diagnosis mentioned in the medical charts; 5 = ICD 9 codes 250.1/250.2/
250.3 from medical charts. Superscript numbers refer to DKA frequency calculated by DKA definitions 1 and 2.
2348 DIABETES CARE, VOLUME 34, NOVEMBER 2011 care.diabetesjournals.org
Participation in TEDDY reduces DKA
SEARCH for Diabetes in Youth
(SEARCH). SEARCH is a U.S. multicen-
ter study aimed at identifying prevalent and
incident cases of diabetes among individu-
als,20 years of age at diagnosis. For these
analyses, we included children diagnosed
with type 1 diabetes in 2004 and 2005.
DKA was defined in the SEARCH protocol
using medical abstraction to identify bicar-
bonate,15 mmol/L or venous pH,7.25
(arterial/capillary pH,7.30), International
Classification of Diseases, Ninth Revision,
code 250.1, or physician’s diagnosis of
DKA. Our analysis included 275 SEARCH
subjects diagnosed with type 1 diabetes
when ,5 years of age.
Swediabkids. Swediabkids is the Swedish
pediatric national quality registry for type
1 diabetes, covering 100% of all children
diagnosed in Sweden. The incidence regis-
ter is part of this national online follow-up
quality register for pediatric patients, where
all pediatric diabetes clinic visits are re-
corded. In this report, we include data from
651 Swedish children diagnosed with type
1 diabetes between 2005 and 2009 and,5
years of age at diagnosis. Of those, 44 chil-
dren were excluded from this analysis due
to missing pH or bicarbonate values. DKA
was defined as arterial pH ,7.30 and se-
vere if arterial pH was ,7.10.
Finnish Diabetes Register. The Finnish
Pediatric Diabetes Register was established
in 2002 and collects data on all children in
Finland diagnosed with type 1 diabetes.
Diabetes was diagnosed according to
World Health Organization criteria, and
DKA was diagnosed as arterial pH ,7.30
and considered severe if arterial pH was
,7.10. In children without arterial pH or
bicarbonate data, negative urine ketones,
negative blood ketones, or lack of symp-
toms (polyuria, polydipsia, and polypha-
gia) were used to exclude DKA. Our
analysis includes 737 children aged ,5
years from the Finnish Diabetes Register
diagnosed with type 1 diabetes from 2005
to 2009.
DPV. The German/Austrian diabetes doc-
umentation and quality management sys-
tem (DPV) is a continuous diabetes data
acquisition system providing data from
53,485 type 1 diabetes patients through-
out Germany and Austria. DKA is defined
in the DPV as arterial pH ,7.30 and se-
vere DKA as arterial pH ,7.10. In pa-
tients without biochemical data, chart
abstraction and physician attestation of
the patient’s condition at diagnosis is con-
sidered sufficient to rule out DKA. Our
analysis includes 1,812 DPV children
from the DPV diagnosed with diabetes
from 2005 to 2009.
Definition of DKA
Because of differences in data collection
and management of newly diagnosed pa-
tients within TEDDY, SEARCH, and the
population-based registries, we used two
definitions of DKA to ensure appropriate
comparisons (Table 2). When comparing
TEDDY data to the Swedish register, strict
criteria for DKA were used and included
arterial pH ,7.30 (venous pH ,7.25) or
standardizedbicarbonate,15mmol/L. Se-
vere DKAwas defined as arterial pH,7.10
or standardized bicarbonate ,5 mmol/L.
For comparisons with SEARCH, German-
DPV, and Finnish registers, broad criteria
for DKA were used to include the strict cri-
teria and, in cases where pH or bicarbonate
values were missing, betahydroxybutyrate
.3.0 mmol/L, urine ketones .40 mg/dL,
or physician’s diagnosis.
Statistical analysis
Data were analyzed using the Statistical
Analysis System Software (Version 9.2;
SAS Institute, Cary, NC). Prevalence esti-
mates and 95% confidence intervals were
calculated as the proportion presenting
with DKA at the time of diagnosis by age-
group (,2 and ,5 years) based on ap-
propriate definition (strict or broad).
Rates were compared using x2 statistics
or Fisher exact test (for small samples,
less than or equal to five per cell) to assess
overall differences in prevalence estimates
by study.
RESULTSdTEDDY screened 424,788
children for type 1 diabetes HLA risk,
identified 21,588 eligible subjects, and
enrolled 8,677 children. As of 31December
2010, 80 TEDDY subjects were diagnosed
with type 1 diabetes (Supplementary Fig.
1). Of those, 40 children were,2 years of
age and 79 were,5 years of age at diagno-
sis. The mean (range) HbA1c (using Na-
tional Glycohemoglobin Standardization
Program standards) at diagnosis was 7.8%
(5.0–13.3). Forty-three of the newly diag-
nosed children were males, and themedian
(range) age inmonths was 23.8 (8–55). De-
spite the relatively young age of the new
onset cohort, 24 of 79 (30%) were asymp-
tomatic at diagnosis. Of the asymptomatic
children, 16 were from the general popula-
tion (representing 29% of the newly diag-
nosed general population subjects)whereas
8 were from first degree–relative families
(representing 33% of newly diagnosed
first-degree relatives).
DKA in children <2 years of age
In children,2 years of age at diagnosis, 6
of 40 (15%) had DKA under the broad def-
inition of DKA whereas 5 of 31 (16.1%)
had DKA under the strict definition of
DKA. TEDDY children diagnosed with
type 1 diabetes before 2 years of age had
lower rates of mild and total DKA when
compared with population-based studies
and registries (SEARCH, P , 0.0001;
German DPV register, P , 0.0001;
Table 2dDefinitions of DKA
Study/register Definition of DKA
TEDDY Strict definition: DKA, arterial pH ,7.30 or bicarbonate ,15 mmol/L; severe DKA, arterial pH ,7.10 or bicarbonate
,5 mmol/L. Broad definition: DKA, arterial pH ,7.30 or bicarbonate ,15 mmol/L. If pH and bicarbonate values
missing, DKA was diagnosed if urine ketones .40 mg/dL, blood ketones .3.0 mmol/L, or by physician’s diagnosis.
Swediabkids DKA, arterial pH ,7.30 (primary) or bicarbonate ,15 (secondary); severe DKA, arterial pH ,7.10 or bicarbonate ,5
mmol/L.
SEARCH DKA, bicarbonate ,15 mmol/L, venous pH ,7.25 or arterial pH ,7.30 or International Classification of Diseases,
Ninth Revision, code 250.1, or physician’s diagnosis of DKA.
Finnish Pediatric
Diabetes Registry DKA, arterial pH ,7.30; severe DKA, arterial pH ,7.10. In children without pH or bicarbonate data, negative urine
ketones, negative blood ketones, or lack of symptoms (polyuria, polydipsia, polyphagia) were used to exclude DKA.
German DPV Registry DKA, arterial pH ,7.30; severe DKA, arterial pH ,7.10. In patients without biochemical data, chart abstraction and
physician attestation of the patient’s condition at diagnosis was used to exclude DKA.
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Swediabkids, P = 0.02; Finnish register,
P = 0.0005) (Table 3).
DKA in children <5 years of age
In children,5 years of age at diagnosis, 9
of 79 (11.3%) had DKA at diagnosis of di-
abetes under the broad definition of DKA.
Using the strict definition of DKA and ex-
cluding those with insufficient data, 8 of 61
(13.1%),5 years of age had DKA at diag-
nosis of diabetes.
Total DKA (mild and severe DKA) at
diagnosis was significantly less common
in TEDDY participants (11.3%) when
compared with SEARCH (36.4%) (P ,
0.0001) and German DPV (25.3%) (P #
0.0001) children, respectively, but were
not statistically different from DKA at di-
agnosis for patients from the Swedish
(16.9%) (P = 0.45) or Finnish (18.7%)
(P = 0.11) registers.
Severe DKA
Although numbers were small, the rate of
severe DKA (arterial pH ,7.10) did not
differ significantly between children diag-
nosed within the TEDDY study and those
reported fromnational registries in any age-
group. Notably, all three TEDDY children
diagnosed with severe DKA were,2 years
of age (8, 10, and 14 months, respectively)
and had developed islet autoantibodies be-
fore clinical presentation of disease.
CONCLUSIONSdIn this study we
compared the prevalence of DKA in chil-
dren participating in TEDDY and diag-
nosed with type 1 diabetes before the age
of 5 years with national population-based
registers. Our analyses demonstrate that
TEDDY subjects diagnosed with type 1
diabetes before the age of 2 years experi-
enced significantly less DKA at diagnosis
(15%) when compared with new-onset
patients reported in national diabetes
registers from countries participating in
TEDDY and the SEARCH study (35–
50%). Similarly, TEDDY children diag-
nosed with type 1 diabetes before the
age of 5 years experienced less DKA at
onset when compared with children in
the SEARCH study and the German
DPV Registry, but not compared with
children from the Finnish or Swedish reg-
istries. Although the relatively high pro-
portion of TEDDY subjects who were
first-degree relatives of type 1 diabetes pa-
tients may have confounded our analysis,
DKA rates within the TEDDY cohort were
similar among children recruited from the
general population and those with a
first-degree relative with type 1 diabetes,
indicating that knowledge of diabetes risk
and close longitudinal follow-up may be
associated with reduced DKA risk regard-
less of family history.
Although our analysis is strengthened
by the inclusion of data from a national
incidence study and registries performed
in each of the countries participating in
TEDDY, we should note that children with
incident diabetes from Colorado and
Washington could have simultaneously
been included in both the SEARCH and
TEDDY databases, and the TEDDY partici-
pants in Sweden, Finland, and Germany
could have been included in the national
registries. While such an occurrence could
have biased our data, the effect (given lower
rates of DKA noted in TEDDY) would have
been to mask the differences observed. As
we were still able to document significant
reductions in DKA when comparing
TEDDY to SEARCH and the national reg-
istries, the effect of any potential bias was
likely minimal. Unfortunately, we were
unable to perform an analysis where par-
ticipants in both TEDDY and a population-
based study or registry were excluded.
Perhaps the most challenging issue
related to inclusion of data from multiple
national incidence registries was that of
interpreting data with an appreciation of
the different definitions of DKA used in
each study (Table 2). The SEARCH study
used a composite definition of DKA that
includes standard cutoffs for pH and
bicarbonate but also allows for nonbio-
chemical clinical documentation to ac-
count for DKA status. The Finnish and
DPV registries used standard biochemi-
cal data, but excluded DKA in children
with negative urine ketones, negative
blood ketones, or lack of symptoms. Con-
versely, the Swedish registry relied en-
tirely on biochemical data to document
DKA status. For the purposes of this anal-
ysis, TEDDY defined DKA using both
strict criteria (standard cutoffs for pH and
bicarbonate) and broad criteria (allowing
us to document DKA status on the ba-
sis of urine/blood ketones and clinician
documentation).
When comparing overall DKA rates
in TEDDY participants with children re-
ported in the Swedish and Finnish regis-
try, no significant differences were seen in
children diagnosed before 5 years of age.
However, rates of DKA in TEDDY partici-
pants aged ,5 years were significantly
lower when compared with children from
the U.S. SEARCH study and the German
registry. These observations are concor-
dant with reports that countries with a
high incidence of type 1 diabetes (Finland
and Sweden) report reduced frequencies of
DKA when compared with countries with
lower incidence of type 1 diabetes. De-
creased frequencies of DKA at onset of dis-
ease have been reported from Finland
between 1982 and 2001, with a decrease
from 22.4 to 15.2% in children 0–15 years
of age and a decrease from32.1 to 17.7% in
childrenwith onset before the age of 5 years
(6). That said, the rate of DKA in children
,2 years of age at onset remained unac-
ceptably high (39.1%) (6).On the contrary,
German data from the DPV register did not
reveal reduced frequency of DKA in any
age-group between 1995 and 2007 (8).
In a Swedish study, the incidence of DKA
at onset of type 1 diabetes in children di-
agnosed from 2000 to 2004was 16%, with
no difference reported between age-
groups. However, children ,2 years of
age were not specifically analyzed (15).
The youngest children with new onset
type 1 diabetes (,2 years of age) remain at
high risk of DKA (Table 1) (6). More spe-
cifically, these young children are prone to
severe DKA at onset. Of the children in
TEDDY diagnosed with severe DKA (pH
,7.10), all three were ,2 years of age (8,
10, and14months, respectively). Although
all three were antibody positive prior to di-
agnosis, we should note that because of the
lag time from antibody testing to reporting
of results, the parents of these children
were likely not informed of the antibody
status prior to the diagnosis. As such, rapid
analysis and reporting of antibody status in
high-risk children could further aid in re-
ducing DKA rates.
Unfortunately, our analysis lacked
the power to determine if participation
in TEDDY reduced the risk of severe DKA
in children,2 years of age. That said, the
observation of reduction in overall DKA
in the youngest patients with new-onset
diabetes suggests that participation in a
longitudinal natural history study with
provision of updated autoantibody risk
information, frequent follow-up, and
scheduled laboratory evaluations (auto-
antibodies, HbA1c, glucose, and OGTT)
to diagnose asymptomatic cases is associ-
ated with reduced DKA risk. Although
potentially cost prohibitive outside the
constraints of a research protocol, com-
bined approaches to educate communities
on signs and symptoms of DKA (as in the
Parma, Italy experiments) and to provide
genetic or antibody screening to further
identify high-risk subjects may eventually
be required to achieve the goal of entirely
preventing DKA in children.
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DKA is a serious condition with high
morbidity and risk of developing cerebral
edema (for a review see Levin [19]). Chil-
dren diagnosed with DKA are hospital-
ized and often treated in intensive care
units. An early diagnosis of diabetes
would therefore be directly beneficial
to the child and indirectly beneficial to
society through reduction of morbidity,
mortality, and cost at onset of disease. Ad-
ditionally, early diagnosis and aggressive
management of diabetesmay be beneficial
in allowing for the presence of a larger
functioning b-cell mass, easier metabolic
control, and possible reductions in long-
term complication risk (12,20). Children
diagnosed in an early stage of disease may
also be eligible to participate in interven-
tion trials aimed at protecting remaining
b-cell mass.
In conclusion, intensive longitudinal
follow-up and continuous education re-
garding diabetes risk, as provided in di-
abetes prediction studies such as TEDDY,
may yield direct benefit to young children
diagnosed with type 1 diabetes through
early diagnosis and reduction of DKA
risk. Ongoing efforts to reduce and elim-
inate DKA at diagnosis in young children
are urgently needed.
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